| 1. |
|
|
| 2. |
- Evans, A. O., et al.
(författare)
-
Magnetic properties of deformed dipole bands in Te-110,Te-112
- 2006
-
Ingår i: Physica Scripta. - 0031-8949. ; T125, s. 192-193
-
Tidskriftsartikel (refereegranskat)abstract
- A lifetime analysis using the Doppler-shift attenuation method has been performed on the Tellurium isotopes Te-110,Te-112. The experiment was performed using the Gammasphere array in conjunction with the MICROBALL charged-particle detector. Three strongly coupled bands were previously established in Te-110,Te-112 which were observed up to unusually high spins. In the current experiment, it has been possible to extract lifetime measurements using a Doppler broadened lineshape analysis on one of the Delta I = 1 band structures in Te-110. In contrast to similar Delta I = 1 structures in other nuclei in this mass region, the extracted B(M1) values did not rapidly decrease with increasing angular momentum. Instead, the strongly coupled band in Te-110 represents a deformed 1p-1h structure, rather than a weakly deformed structure showing the shears mechanism.
|
|
| 3. |
- Paul, E. S., et al.
(författare)
-
Smooth terminating bands in Te-112: Particle-hole induced collectivity
- 2007
-
Ingår i: Physical Review C (Nuclear Physics). - 0556-2813. ; 75:1
-
Tidskriftsartikel (refereegranskat)abstract
- The Gammasphere spectrometer, in conjunction with the Microball charged-particle array, was used to investigate high-spin states in Te-112 via Ni-58(Ni-58, 4p gamma) reactions at 240 and 250 MeV. Several smooth terminating bands were established, and lifetime measurements were performed for the strongest one using the Doppler-shift attenuation method. Results obtained in the spin range 18-32h yield a transition quadrupole moment of 4.0 +/- 0.5eb, which corresponds to a quadrupole deformation epsilon(2)=0.26 +/- 0.03; this value is significantly larger than the ground-state deformation of tellurium isotopes. It was also possible to extract a transition quadrupole moment for the yrast band in Xe-114, produced via the 58Ni (58Ni, 2p gamma) reaction. A value of 3.0 +/- 0.5eb was found in the spin range 16-24h, which corresponds to a quadrupole deformation epsilon(2)=0.19 +/- 0.03. Cranked Nilsson-Strutinsky calculations are used to interpret the results.
|
|
| 4. |
|
|
| 5. |
- Sears, M. R., et al.
(författare)
-
Past, present and future--beta2-adrenoceptor agonists in asthma management
- 2005
-
Ingår i: Respir Med. ; 99:2
-
Tidskriftsartikel (refereegranskat)abstract
- The beta-adrenoceptor agonists (beta-agonists) have been used to relieve bronchoconstriction for at least 5000 years. beta-agonists are based on adrenaline and early forms, such as isoprenaline, Lacked bronchial selectivity and had unpleasant side effects. Modern beta-agonists are more selective for the beta2-adrenoceptors (beta2-receptors) located in bronchial smooth muscle and have less cardiotoxicity. Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action. While valuable as reliever medication, their short duration gave inadequate night-time relief and limited protection from exercise-induced bronchoconstriction. beta2-agonists with longer durations of action, formoterol and salmeterol, were subsequently discovered or developed. When combined with inhaled corticosteroids they improved lung function, and reduced symptoms and exacerbations more than an increased dose of corticosteroids. However, tolerance to the bronchprotective effects of long-acting beta2-agonists and cross-tolerance to the bronchodilator effects of short-acting beta2-agonists is apparent despite use of inhaled corticosteroids. The role of beta2-receptor polymorphisms in the development of tolerance has yet to be fully determined. Formoterol is unique in having both a long-lasting bronchodilator effect (> 12 h) and a fast onset of action (1-3min from inhalation), making it effective both as maintenance and reliever medication. The recent change in classification from short- and long-acting beta2-agonists to rapid-acting and/or long-acting agents reflects the ongoing evolution of beta2-agonist therapy.
|
|
| 6. |
|
|
